What is Sudo Biosciences?
Founded in 2020 and headquartered in Menlo Park, California, Sudo Biosciences operates within the dynamic biopharmaceutical sector. The company is dedicated to advancing novel therapeutic solutions, positioning itself at the forefront of medical innovation. Its strategic focus likely involves addressing unmet medical needs through cutting-edge research and development, aiming to translate scientific breakthroughs into tangible patient benefits. The substantial capital raised indicates a strong belief in the company's potential to scale its operations and bring impactful treatments to market.
How much funding has Sudo Biosciences raised?
Sudo Biosciences has raised a total of $184M across 2 funding rounds:
Series A
$37M
Series B
$147M
Series A (2022): $37M, investors not publicly disclosed
Series B (2024): $147M led by Eventide Asset Management, Sanofi Ventures, Enavate Sciences, Frazier Life Sciences Management, Dementia Discovery Fund, TPG, and Surveyor Capital
Key Investors in Sudo Biosciences
Eventide Asset Management
Eventide Asset Management is a mutual fund provider focused on integrity, impact, and outperformance, offering diverse funds including those in healthcare and technology, catering to various investor types with a values-based approach.
Sanofi Ventures
Sanofi Ventures, the corporate venture capital arm of Sanofi, invests in early-stage biotech and digital health companies with innovative products and technologies of strategic interest to Sanofi, particularly in oncology, immunology, and rare diseases.
Frazier Life Sciences Management
Frazier Life Sciences Management is a venture capital firm specializing in novel therapeutics, having managed over $5.3 billion in capital since 2015 and supporting the creation of over 25 companies with a focus on collaboration and integrity.
What's next for Sudo Biosciences?
With the recent influx of major strategic investment, Sudo Biosciences is poised for accelerated growth and expansion. This significant backing is expected to fuel further research and development initiatives, potentially enabling the company to advance its pipeline candidates through critical clinical trial stages and towards commercialization. The enterprise-level funding suggests a focus on scaling operations, enhancing manufacturing capabilities, and potentially forging strategic partnerships to broaden market reach. Sudo Biosciences is likely to leverage this capital to solidify its position as a key player in the biopharmaceutical industry, driving innovation and addressing significant healthcare challenges.
See full Sudo Biosciences company page
